Repligen Co. (NASDAQ:RGEN) Receives Average Recommendation of "Moderate Buy" from Analysts

Repligen Co. (NASDAQ:RGEN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen research firms that are currently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $173.25.

A number of equities analysts recently weighed in on RGEN shares. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group lowered their target price on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Wall Street Zen raised shares of Repligen from a "sell" rating to a "hold" rating in a research note on Thursday, May 8th. HC Wainwright reissued a "buy" rating and set a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Finally, Royal Bank of Canada lowered their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research note on Wednesday, April 30th.

Repligen Trading Down 2.9%

Shares of NASDAQ:RGEN traded down $3.78 during mid-day trading on Wednesday, reaching $127.52. 507,147 shares of the company's stock were exchanged, compared to its average volume of 737,265. The firm has a market capitalization of $7.16 billion, a price-to-earnings ratio of -250.04, a PEG ratio of 4.54 and a beta of 1.11. The business's fifty day moving average price is $128.58 and its 200-day moving average price is $142.91. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a twelve month low of $102.97 and a twelve month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The business had revenue of $169.17 million during the quarter, compared to the consensus estimate of $163.65 million. During the same quarter last year, the firm earned $0.28 earnings per share. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. On average, research analysts predict that Repligen will post 1.72 EPS for the current fiscal year.

Insider Transactions at Repligen

In other Repligen news, Director Margaret Pax bought 250 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. The trade was a 31.53% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. Oppenheimer & Co. Inc. purchased a new position in Repligen during the fourth quarter worth about $216,000. Van ECK Associates Corp lifted its position in shares of Repligen by 7.8% during the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares in the last quarter. LPL Financial LLC boosted its stake in shares of Repligen by 47.6% in the 4th quarter. LPL Financial LLC now owns 32,237 shares of the biotechnology company's stock worth $4,873,000 after buying an additional 10,395 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Repligen by 172.2% in the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares in the last quarter. Finally, US Bancorp DE grew its holdings in shares of Repligen by 1.9% in the fourth quarter. US Bancorp DE now owns 10,222 shares of the biotechnology company's stock valued at $1,471,000 after acquiring an additional 190 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.